CD163 is increased on myeloid cells near neurodegenerative pathology, including PD, while soluble CD163 correlates with exacerbation of inflammation and worsening disease outcomes in neurodegenerative, inflammatory, and autoimmune diseases. This evidence concerns the gene CD163 and Parkinson disease.